menu

Evolving Our View of the Coagulation Cascade and Stroke Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Evolving Our View of the Coagulation Cascade and Stroke Management

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the coagulation cascade and the relevance of inhibiting factors XI and XIa in stroke management.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Valeria Caso, MD, PhD
    Professor of Neurology
    University of Perugia
    Perugia, Italy

    Dr. Caso has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Research: Bayer
    Consulting Fees: Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo, EVER Neuro Pharma, Pfizer, MindMaze

    Ashkan Shoamanesh, MD
    Associate Professor of Medicine
    McMaster University
    Hamilton, Canada

    Dr. Shoamanesh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Research: Bayer
    Consulting Fees: Bayer

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Susan Diaz has nothing to disclose.
    • Vin Kalathiveetil has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Examine the existing therapeutics and their impact on various pathways within the coagulation cascade, consequently heightening the risk of significant bleeding events
    • Discuss the relevance of inhibiting factor XI and factor XIa in stroke management
    • Explore novel and emerging pharmacotherapies for anticoagulation in secondary stroke prevention 
  • Target Audience

    This activity is designed to meet the educational needs of clinical cardiologists, primary care physicians, and neurologists involved in managing patients with an acute ischemic stroke or high-risk TIA.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until May 30, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-049-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)


    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC. you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the coagulation cascade and the relevance of inhibiting factors XI and XIa in stroke management.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Valeria Caso, MD, PhD
    Professor of Neurology
    University of Perugia
    Perugia, Italy

    Dr. Caso has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Research: Bayer
    Consulting Fees: Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo, EVER Neuro Pharma, Pfizer, MindMaze

    Ashkan Shoamanesh, MD
    Associate Professor of Medicine
    McMaster University
    Hamilton, Canada

    Dr. Shoamanesh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:

    Research: Bayer
    Consulting Fees: Bayer

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Susan Diaz has nothing to disclose.
    • Vin Kalathiveetil has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Examine the existing therapeutics and their impact on various pathways within the coagulation cascade, consequently heightening the risk of significant bleeding events
    • Discuss the relevance of inhibiting factor XI and factor XIa in stroke management
    • Explore novel and emerging pharmacotherapies for anticoagulation in secondary stroke prevention 
  • Target Audience

    This activity is designed to meet the educational needs of clinical cardiologists, primary care physicians, and neurologists involved in managing patients with an acute ischemic stroke or high-risk TIA.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until May 30, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/.025 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-24-049-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)


    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME, LLC. you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule14 Jun 2024